

Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma

Chengli Song¹, Lina Wang¹, Qiang Xu¹, Kai Wang¹, Dan Xie¹, Zhe Yu¹, Kui Jiang¹, Lujian Liao², John R. Yates III³, Jiing-Dwan Lee⁴ & Qingkai Yang¹

Supplementary Figure legends

Supplementary Figure S1. Phosphoproteomic profiling revealed that the upregulated phosphosites were enriched in phospho-tyrosine sites and MAPK pathways. **(a)** Number of gene enriched according to subcellular localizations as noted. **(b)** Percentage of gene enriched according to subcellular localizations as noted. **(c)** Number of gene enriched according to molecular functions. **(d)** Percentage of gene enriched according to molecular functions. **(e)** Number of gene enriched according to biological processes. **(f)** Percentage of gene enriched according to biological processes.

Supplementary Figure S2. Phosphorylation of ERK1/2 in CIBM resistant cell lines in Fig. 3c and 3d. Phospho- ERK1/2 was evaluated using western blotting as noted.

Supplementary Figure S3. Microarray analysis of A375-P cells treated with/without BMK1 inhibitor, XMD8-92. **(a)** Heatmap of microarray assay data from three individual experiments. A375-P cells were treated with/without 2 μ M XMD8-92 for 24 hrs. RNA was extracted using the miRNeasy Mini Kit from QIAGEN (QIAGEN, Hilden, Germany) according to the manufacturer's instruction. Microarray experiments were performed in triplicate as noted. And the microarray data are described in Supplementary Table S5. **(b)** Number of gene enriched according to subcellular localization as noted. **(c)** Number of gene enriched according to molecular function. **(d)** Number of gene enriched according to biological process. **(e)** Number of gene enriched according to pathway analysis.





